There are plenty of unknowns surrounding the concept of a “progressive approval” system, but one thing is clear in the eyes of FDA Office of New Drugs Director John Jenkins – there should be no lowering of the efficacy bar.
During a panel discussion at Elsevier Business Intelligence’s FDA/CMS Summit on Dec. 8, Jenkins was asked to comment on proposals...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?